The FDA granted Emergency Use Authorization (EUA) to the Novavax COVID-19, Adjuvanted vaccine for individuals aged 18 and older. This vaccine is administered in two primary doses given three weeks apart. The vaccine was assessed in an ongoing randomized, blinded, placebo-controlled study involving 17,200 people. Overall, the vaccine was 90.4% effective in preventing mild, moderate or severe COVID-19. This vaccine utilizes a different technology than other COVID-19 vaccines, and was recently endorsed by the Centers for Disease Control and Prevention.
